Ramaswamy Govindan, M.D., KRAS Targeted Therapies, KRAS Kickers Connect, September 25, 2021

preview_player
Показать описание
Ramaswamy Govindan, M.D., Washington University School of Medicine, speaks about KRAS Targeted Therapies, Clinical Trials and Scientific Studies during the inaugural KRAS Kickers Connect event held on September 25, 2021 in Charlotte, NC.

We are in this together to kick cancer's KRAS!
Is your KRAS Wild? or KRAS Mutant? Ask your doc!

Visit our website:

Facebook

Twitter

Instagram
  1. KRAS Kickers
Рекомендации по теме
Ramaswamy Govindan, M.D., 0:43:27

Ramaswamy Govindan, M.D., KRAS Targeted Therapies, KRAS Kickers Connect, September 25, 2021

Researcher comment: AMG 0:05:34

Researcher comment: AMG 510 for KRAS mutation-positive NSCLC | Ramaswamy Govindan

Govindan Discusses the 0:03:55

Govindan Discusses the Phase I Results of AMG 510 Evaluated in NSCLC

Lung Cancer History 0:55:11

Lung Cancer History and Updates

Targeted Therapy for 0:02:49

Targeted Therapy for KRAS p.G12C NSCLC

Ramaswamy Govindan, Washington 0:33:11

Ramaswamy Govindan, Washington University School of Medicine, USA:

Dr. Govindan on 0:00:48

Dr. Govindan on the Future of EGFR-Mutant NSCLC

Targeted Therapy for 0:07:23

Targeted Therapy for KRAS-Mutant NSCLC

KRAS G12C Inhibition 0:04:09

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Expert Discusses KRAS 0:01:37

Expert Discusses KRAS G12C Inhibitors for Patients with NSCLC

AMG 510 for 0:04:06

AMG 510 for targeting KRAS G12C mutant solid tumours

Dr. Ou on 0:02:32

Dr. Ou on Investigational KRAS Inhibitors in Lung Cancer

Debate: What is 0:10:06

Debate: What is the optimal timing for EGFR-targeted therapy? - Favor frontline therapy

What’s on the 0:07:34

What’s on the Horizon for Immunotherapy in NSCLC?

Strategies for Overcoming 0:21:36

Strategies for Overcoming KRAS Mutations

In-Depth KRAS Biomarker 0:03:38

In-Depth KRAS Biomarker in Lung Cancer | Hope With Answers℠

ESMO 2014: Lung 0:22:33

ESMO 2014: Lung Cancer

Onvansertib for second-line 0:02:39

Onvansertib for second-line treatment of KRAS-mutated mCRC

Dr. Fakih on 0:01:08

Dr. Fakih on the Safety Profile of AMG 510 in KRAS G12C-Mutated CRC

Grand Rounds 2021.01.27 0:55:41

Grand Rounds 2021.01.27

Expert Perspectives: Lung 0:18:41

Expert Perspectives: Lung Cancer

AMG 510 KRAS 0:03:41

AMG 510 KRAS Inhibitor trial results – ‘A good start’ | Colin Lindsay

This Research Could 0:08:15

This Research Could Change Cancer Treatment Forever

AMG 510: A 0:03:26

AMG 510: A novel molecule targeting KRAS G12C mutatant solid tumours